PROPOFOL

ECT

Min SuSmall moleculeEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 89/ 100

Competitive context

3 Active assets in the ECT cohort.

Asset / Sponsor	Phase	Rating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Bo Hu	Phase 2/3	B
Erythropoietin Human Recombinant Martin Balslev Jørgensen	Phase 2	B
S-Ketamine Min Su	Early Phase 1	C
SUXAMETHONIUM CHLORIDE Min Su	Early Phase 1	C
FLUMAZENIL Anders Jørgensen	N/A	D

Same molecule, other indications

PROPOFOL is also rated in:

Pain, ChronicDormant

BBB

Indicative ·

79 / 100

headache disorderDormant

BBB

Indicative ·

73 / 100

morbid obesityDormant

BBB

Indicative ·

73 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.